CDK4 and prostate carcinoma: Studies evaluating CDK4/6 inhibitors in prostate cancer should assess if selective pressure leads to increased RB1 loss and increased small-cell transformation in prostate cancer patients, as this would constitute a significant treatment-related adverse event [142,143].